Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more
Sutro Biopharma (STRO) - Net Assets
Latest net assets as of September 2025: $-87.27 Million USD
Based on the latest financial reports, Sutro Biopharma (STRO) has net assets worth $-87.27 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($209.66 Million) and total liabilities ($296.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-87.27 Million |
| % of Total Assets | -41.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.57% |
| 10-Year Change | N/A |
| Growth Volatility | 103.1 |
Sutro Biopharma - Net Assets Trend (2016–2024)
This chart illustrates how Sutro Biopharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sutro Biopharma (2016–2024)
The table below shows the annual net assets of Sutro Biopharma from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $44.60 Million | -70.20% |
| 2023-12-31 | $149.65 Million | -31.05% |
| 2022-12-31 | $217.05 Million | -14.06% |
| 2021-12-31 | $252.56 Million | -23.94% |
| 2020-12-31 | $332.05 Million | +239.56% |
| 2019-12-31 | $97.79 Million | -25.66% |
| 2018-12-31 | $131.54 Million | +220.68% |
| 2017-12-31 | $-109.00 Million | -19.91% |
| 2016-12-31 | $-90.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sutro Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69154600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $83.00K | 0.19% |
| Other Comprehensive Income | $39.00K | 0.09% |
| Other Components | $831.35 Million | 1863.97% |
| Total Equity | $44.60 Million | 100.00% |
Sutro Biopharma Competitors by Market Cap
The table below lists competitors of Sutro Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Currenc Group Inc. Ordinary Shares
NASDAQ:CURR
|
$79.09 Million |
|
Cardiol Therapeutics Inc Class A
NASDAQ:CRDL
|
$79.10 Million |
|
Alpha Cognition Inc
NASDAQ:ACOG
|
$79.11 Million |
|
Kenilworth Systems C
PINK:KENS
|
$79.13 Million |
|
Mercer International Inc
NASDAQ:MERC
|
$79.08 Million |
|
American Lithium Corp. Common Stock
NASDAQ:AMLI
|
$79.01 Million |
|
Kerevitas Gida Sanayi ve Ticaret AS
IS:KERVT
|
$79.01 Million |
|
Townsquare Media Inc
NYSE:TSQ
|
$79.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sutro Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 149,649,000 to 44,601,000, a change of -105,048,000 (-70.2%).
- Net loss of 227,461,000 reduced equity.
- New share issuances of 96,527,000 increased equity.
- Other comprehensive income increased equity by 18,000.
- Other factors increased equity by 25,868,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-227.46 Million | -509.99% |
| Share Issuances | $96.53 Million | +216.42% |
| Other Comprehensive Income | $18.00K | +0.04% |
| Other Changes | $25.87 Million | +58.0% |
| Total Change | $- | -70.20% |
Book Value vs Market Value Analysis
This analysis compares Sutro Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-2060.31 | $22.94 | x |
| 2017-12-31 | $-15.58 | $22.94 | x |
| 2018-12-31 | $57.53 | $22.94 | x |
| 2019-12-31 | $42.59 | $22.94 | x |
| 2020-12-31 | $10.19 | $22.94 | x |
| 2021-12-31 | $54.76 | $22.94 | x |
| 2022-12-31 | $42.78 | $22.94 | x |
| 2023-12-31 | $24.87 | $22.94 | x |
| 2024-12-31 | $5.81 | $22.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sutro Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -509.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -366.62%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 8.68x
- Recent ROE (-509.99%) is below the historical average (-85.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 2.85% | 0.86x | 0.00x | $10.79 Million |
| 2017 | 0.00% | -38.05% | 1.27x | 0.00x | $-8.79 Million |
| 2018 | -26.85% | -91.93% | 0.17x | 1.70x | $-48.47 Million |
| 2019 | -57.00% | -130.44% | 0.27x | 1.60x | $-65.52 Million |
| 2020 | -9.68% | -75.20% | 0.11x | 1.19x | $-65.33 Million |
| 2021 | -41.79% | -170.55% | 0.18x | 1.35x | $-130.79 Million |
| 2022 | -54.92% | -175.89% | 0.17x | 1.87x | $-140.91 Million |
| 2023 | -71.36% | -69.47% | 0.33x | 3.15x | $-121.76 Million |
| 2024 | -509.99% | -366.62% | 0.16x | 8.68x | $-231.92 Million |
Industry Comparison
This section compares Sutro Biopharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sutro Biopharma (STRO) | $-87.27 Million | 0.00% | N/A | $79.09 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |